A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Clinical Trial ID NCT00994123

Rank	Title	Journal	Year	PubWeight™‹?›
1	New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer.	Clin Cancer Res	2011	2.74
2	Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3.	J Clin Invest	2013	2.11
3	Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.	Sci Signal	2013	1.96
4	Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.	Clin Cancer Res	2014	1.33
5	Molecular pathways and therapeutic targets in lung cancer.	Oncotarget	2014	1.16
6	Regulation of ERBB3/HER3 signaling in cancer.	Oncotarget	2014	1.00
7	ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.	PLoS One	2016	0.91
8	Targeting genomic alterations in squamous cell lung cancer.	Front Oncol	2013	0.85
9	Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.	Onco Targets Ther	2013	0.85
10	A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.	Am J Transl Res	2015	0.83
11	Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials.	Curr Oncol	2012	0.81
12	Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.	Hum Vaccin Immunother	2015	0.81
13	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.	MAbs	2016	0.77